Drug Trial Radar · NCT06885021
Evaluate the Safety and Efficacy of HDM1002 Tablets in Chinese Overweight and Obese Adults
Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
780
Planned (sponsor's estimate)
Start
Mar 28, 2025
Primary completion
May 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3 Trial to Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
Conditions
- Overweight and Obesity
Interventions
HDM1002 200mg, oral, once daily, 52 weeksDrug
HDM1002 200mg, oral, once daily, 52 weeks
HDM1002 400mg, oral, once daily, 52 weeksDrug
HDM1002 400mg, oral, once daily, 52 weeks
HDM1002 placebo, oral, once daily, 52 weeksDrug
HDM1002 placebo, oral, once daily, 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change From Baseline in Body WeightTime frame: 44weeks
- Percentage Change of Participants Achieving Weight Loss ≥ 5%Time frame: 44weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.